Viral vector vaccines utilize a harmless virus to deliver genetic material from a pathogen into human cells, prompting an immune response without causing disease. This innovative approach combines the efficiency of live vaccines with the safety of inactivated ones, offering a promising solution for rapid vaccine development against emerging infectious diseases.

Viral Vector Vaccines

Harmless virus

Genetic material is the molecular basis of inheritance, encoding the information necessary for the development, function, and reproduction of living organisms. It primarily consists of DNA and RNA, which carry genetic instructions in the form of sequences of nucleotides.

Genetic Material

The immune response is the body's defense mechanism against pathogens, involving a complex interplay between innate and adaptive immunity. It includes the recognition of foreign antigens, activation of immune cells, and the elimination of pathogens, while also maintaining tolerance to self-antigens to prevent autoimmunity.

Immune Response

Live vaccines

Inactivated ones

Vaccine development is a complex, multi-stage process that involves initial research, preclinical testing, and multiple phases of clinical trials to ensure safety and efficacy before regulatory approval and mass production. This process can take several years, but advancements in technology and global collaboration have accelerated timelines, as seen with the COVID-19 vaccines.

Vaccine Development

Emerging infectious diseases are infections that have recently increased in incidence or geographic range, or are expected to increase in the near future, often due to factors like globalization, environmental changes, and human behavior. These diseases pose significant challenges to public health systems worldwide, necessitating robust surveillance, rapid response, and international cooperation to prevent outbreaks and mitigate their impact.

Concepts

Relevant Degrees

Your Lessons